



RECEIVED
JAN 30 2001
TECH CENTER 1600/2909

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.

9516-018-999

APPLICATION NO.

09/734,460

APPLICANT

Jerome B. Zeldis

FILING DATE

December 11, 2000

GROUP

To be assigned

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
CLZ	AA	3,536,809	10/27/70	Applezweig			
	AB	3,598,123	8/10/71	Zaffaroni			
	AC	3,845,770	11/05/74	Theeuwes et al.			
	AD	3,916,899	11/04/75	Theeuwes et al.			
	AE	4,008,719	2/22/77	Theeuwes, et al.			
	AF	5,059,595	10/22/91	LeGrazie			
	AG	5,073,543	12/17/91	Marshall, et al.			
	AH	5,120,548	6/09/92	McClelland, et al.			
	AI	5,354,556	10/11/94	Sparks, et al.			
	AJ	5,591,767	1/07/97	Mohr, et al.			
	AK	5,593,990	1/14/97	D'Amato			
	AL	5,605,914	2/25/97	Muller			
	AM	5,629,327	5/13/97	D'Amato			
	AN	5,635,517	6/03/97	Muller et al.			
	AO	5,637,113	6/10/97	Tartaglia, et al.			
	AP	5,639,476	6/17/97	Oshlack, et al.			
	AQ	5,658,940	8/19/97	Muller et al.			
	AR	5,674,533	10/07/97	Santus et al.			
	AS	5,698,579	12/16/97	Muller			
	AT	5,703,098	12/30/97	Muller et al.			
	AU	5,728,844	3/17/98	Muller et al.			
	AV	5,728,845	3/17/98	Muller et al.			
	AW	5,733,566	3/31/98	Lewis			
	AX	5,736,570	4/07/98	Muller et al.			
	AY	5,798,368	8/25/98	Muller et al.			
	AZ	5,801,195	9/01/98	Muller et al.			
	BA	5,837,313	11/17/98	Ding et al.			
	BB	5,874,448	2/23/99	Muller et al.			
CLZ	BC	5,877,200	3/02/99	Muller			

FOREIGN PATENT DOCUMENTS									
		DOCUMENT NUMBER	TE	COUNTRY	CLASS	SUBCLASS	TRANSLATION		
							YES	NO	
CE	BE	WO 99/06041	2/11/99	PCT					
OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)									
		Amols, et al., 1998, "Intracoronary radiation for prevention of restenosis: dose perturbations caused by stents", Circulation 98(19):2024-9.							
		Bachelerie et al., 1991, "HIV enhancer activity perpetuated by NF-kappa B induction on infection of monocytes", Nature 350(6320):709-12							
		Blaschke et al., 1979, "Chromatographic separation of racemic thalidomide and teratogenic activity of its enantiomers", Arzneimittelforschung 29(10):1640-2.							
	BI	Brem, et al., 1991, "Interstitial chemotherapy with drug polymer implants for the treatment of recurrent gliomas", J Neurosurg. 74(3):441-6.							
	BJ	Casini, et al., 1964, Farmaco Ed. Sci. 19:563							
	BK	D'Amato et al., 1994, "Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci U S A 91(9):4082-5.							
	BL	Dbaibo et al., 1993, "Tumor necrosis factor-alpha (TNF-alpha) signal transduction through ceramide. Dissociation of growth inhibitory effects of TNF-alpha from activation of nuclear factor-kappa B", J Biol Chem. 268(24):17762-6.							
	BM	Duh et al., 1989, "Tumor necrosis factor alpha activates human immunodeficiency virus type 1 through induction of nuclear factor binding to the NF-kappa B sites in the long terminal repeat", Proc Natl Acad Sci U S A. 86(15):5974-8.							
	BN	Eltchaninoff, et al., 1998, "Balloon angioplasty for the treatment of coronary in-stent restenosis: immediate results and 6-month angiographic recurrent restenosis rate. J Am Coll Cardiol. 32(4):980-4.							
	BO	Libby et al., 1992, "A cascade model for restenosis. A special case of atherosclerosis progression", Circulation. 86(6 Suppl):III47-52.							
	BP	Moreno et al., 1996, "Macrophage infiltration predicts restenosis after coronary intervention in patients with unstable angina", Circulation 94(12):3098-102.							
	BQ	Muller, et al. "Thalidomide: From tragedy to new drug discovery", 1997, Chemtech 27(1):21-25							
	BR	Shealy et al., 1965, "D- and L-thalidomide", Chem Ind. 24:1030-1.							
	BS	Suzuki and Packer. 1993, "Inhibition of NF-kappa B activation by vitamin E derivatives", Biochem Biophys Res Commun. 193(1):277-83							
	BT	Takano, et al., 1998, "High levels of circulating Macrophage Colony Stimulating Factor (M-CSF) Predict Restenosis After Primary Angioplasty in Patients With Acute Myocardial Infraction", Circulation 98(17, supp):4437.							
CE	BU	Tardif et al., 1991, "Probuco and multivitamins in the prevention of restenosis after coronary angioplasty", N Engl J Med. 337(6):365-72.							
EXAMINER				DATE CONSIDERED					
Charesse L. Evans				3.5.2002					
<p>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>									

RECEIVED Sheet 1 of 1

MAY 17 2001

TECH CENTER 1600/2900

LIST OF REFERENCES CITED BY APPLICANT <i>(Use several sheets if necessary)</i>					ATTY. DOCKET NO.		APPLICATION NO.	
					9516-018-999		09/734,460	
					APPLICANT			
					Jerome B. Zeldis			
					FILING DATE		GROUP	
					December 11, 2000		1614	

U.S. PATENT DOCUMENTS								
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE	
CLE	BV	5,849,736	12/15/98	Wityak et al.				

FOREIGN PATENT DOCUMENTS								
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
CLE	BW	WO 00/10552	3/2/2000	PCT				
	BX	WO 99/58096	11/18/99	PCT				
	BY	WO 98/08840	3/5/98	PCT				
	BZ	WO 96/11209	4/18/96	PCT				
CLE	CA	0 688 771	12/27/95	EPO (In German)				X

OTHER REFERENCES <i>(Including Author, Title, Date, Pertinent Pages, Etc.)</i>		

EXAMINER <i>Charesse J. Evans</i>	DATE CONSIDERED <i>35.02</i>
-----------------------------------	------------------------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with **MPEP 609**; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.